Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Equity Average (2017 - 2025)

Historic Equity Average for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Q3 2025 value amounting to $68.5 million.

  • Rhythm Pharmaceuticals' Equity Average rose 17079.59% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year increase of 17079.59%. This contributed to the annual value of $95.7 million for FY2024, which is 5588.05% down from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Equity Average stood at $68.5 million, which was up 17079.59% from $3.5 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Equity Average peaked at $366.3 million during Q2 2021, and registered a low of $3.5 million during Q2 2025.
  • Moreover, its 5-year median value for Equity Average was $201.0 million (2023), whereas its average is $178.9 million.
  • Over the last 5 years, Rhythm Pharmaceuticals' Equity Average had its largest YoY gain of 17079.59% in 2025, and its largest YoY loss of 9302.54% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Equity Average (Quarter) stood at $303.2 million in 2021, then fell by 10.05% to $272.7 million in 2022, then plummeted by 32.67% to $183.6 million in 2023, then tumbled by 91.03% to $16.5 million in 2024, then skyrocketed by 315.58% to $68.5 million in 2025.
  • Its Equity Average was $68.5 million in Q3 2025, compared to $3.5 million in Q2 2025 and $20.3 million in Q1 2025.